Physician

Nelli Bejanyan, M.D.

According to 2025 Medicare claims, Nelli Bejanyan, M.D. (NPI: 1205009024) practices hematopoietic cell transplantation and cellular therapy in the Cape Coral-Fort Myers, FL market, with the plurality of this provider's patient population coming from Lee, FL. This provider's primary affiliated billing organization is H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (NPI: 1306833595; TIN: 593238640) and primary practice location at 33612-9416.

Bejanyan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 44 traditional Medicare patients, billed 226 HCPCS/CPT codes, and received $14,228 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 244 prescription claims across 36 beneficiaries totaling $982,259 in drug costs, led by Rezurock (Belumosudil Mesylate). DME data shows 31 claims. Open Payments data shows 8 records totaling $11,931. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $19,573 and ending at $14,228. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $291,252 and ending at $982,259. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	41	254	$19,573
2016	46	165	$12,087
2017	48	233	$18,129
2018	61	302	$26,084
2019	54	183	$15,975
2020	66	380	$32,533
2021	57	297	$29,134
2022	45	194	$17,872
2023	42	136	$11,301
2024	44	226	$14,228

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	30	210	$291,252
2016	27	319	$712,548
2017	32	253	$487,231
2018	32	163	$206,661
2019	25	178	$108,959
2020	45	394	$193,868
2021	33	329	$327,310
2022	34	207	$214,297
2023	31	205	$574,700
2024	36	244	$982,259

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	26	$4,130
2020	N/R	13	$738
2021	N/R	N/R	N/R
2022	N/R	23	$3,920
2023	N/R	N/R	N/R
2024	N/R	31	$562

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	27	37	$113
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	25	80	$77
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	11	30	$25
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	21	45	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rezurock	Belumosudil Mesylate	17	510	$502,458
Jakafi	Ruxolitinib Phosphate	30	900	$364,687
Atovaquone	Atovaquone	23	677	$9,996
Ursodiol	Ursodiol	20	600	$1,792
Acyclovir	Acyclovir	26	1,470	$594

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$282
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	16	$279

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$2,108	Medexus Pharma, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	6	$9,823	Moffitt Cancer Center
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Nelli Bejanyan, M.D.?

Tedicare shows public-source Medicare data for Nelli Bejanyan, M.D. (NPI 1205009024), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Nelli Bejanyan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Nelli Bejanyan, M.D.?

Nelli Bejanyan, M.D. is linked to H LEE MOFFITT CANCER CTR & RES INST LIFE TIME CANCER SCRN CTR INC (billing NPI 1306833595) in the available physician profile data.

Does Nelli Bejanyan, M.D. have Open Payments data?

Nelli Bejanyan, M.D. has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.